Question 1

What is Bristol-Myers Squibb's P/E ratio?

Accepted Answer

Bristol-Myers Squibb (BMY) P/E ratio is 17.1× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Bristol-Myers Squibb?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Bristol-Myers Squibb specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Bristol-Myers Squibb's P/E ratio high or low?

Accepted Answer

Bristol-Myers Squibb's P/E ratio of 17.1× is below its own 5-year average of 19.2× and below the sector median of 24.2×. That places the current reading at the 33th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Bristol-Myers Squibb's historical P/E ratio range?

Accepted Answer

In the available daily series, Bristol-Myers Squibb (BMY) P/E ratio has ranged from a low of 4.0× in 2010 to a high of 240.3× in 2018. The 5-year average is 19.2× and the 5-year median is 18.9×.

Question 7

What was Bristol-Myers Squibb's P/E ratio in 2025?

Accepted Answer

Bristol-Myers Squibb (BMY) P/E ratio at the end of 2025 was 15.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Bristol-Myers Squibb's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$110B	$7.05B	15.6×	—	Dec 31, 2025
2024	$115B	-$8.95B	—	—	Dec 31, 2024
2023	$104B	$8.03B	13.0×	-11.0×	Dec 31, 2023
2022	$152B	$6.33B	24.0×	+4.8×	Dec 31, 2022
2021	$134B	$6.99B	19.2×	—	Dec 31, 2021
2020	$140B	-$9.02B	—	—	Dec 31, 2020
2019	$123B	$3.44B	35.7×	+18.5×	Dec 31, 2019
2018	$84.8B	$4.92B	17.2×	-82.3×	Dec 31, 2018
2017	$100B	$1.01B	99.6×	+77.6×	Dec 31, 2017
2016	$97.7B	$4.46B	21.9×	-50.6×	Dec 31, 2016
2015	$113B	$1.57B	72.5×	+23.6×	Dec 31, 2015
2014	$98B	$2B	48.9×	+14.7×	Dec 31, 2014
2013	$87.6B	$2.56B	34.2×	+6.8×	Dec 31, 2013
2012	$53.6B	$1.96B	27.3×	+11.3×	Dec 31, 2012
2011	$59.6B	$3.71B	16.1×	+1.5×	Dec 31, 2011
2010	$45.2B	$3.1B	14.6×	+9.9×	Dec 31, 2010
2009	$49.5B	$10.6B	4.7×	-4.1×	Dec 31, 2009
2008	$46B	$5.25B	8.8×	-15.4×	Dec 31, 2008
2007	$52.4B	$2.17B	24.2×	-8.4×	Dec 31, 2007
2006	$51.7B	$1.59B	32.6×	+17.6×	Dec 31, 2006
2005	$44.9B	$3B	15.0×	-5.9×	Dec 31, 2005
2004	$49.8B	$2.39B	20.9×	+3.3×	Dec 31, 2004
2003	$55.5B	$3.15B	17.6×	-6.8×	Dec 31, 2003
2002	$50.5B	$2.07B	24.4×	—	Dec 31, 2002


Agilent Technologies (A)	23.1×
Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Bristol-Myers Squibb (BMY) 2002-2026

P/E Ratio daily chart for Bristol-Myers Squibb (BMY)

Historical P/E Ratio for Bristol-Myers Squibb (BMY) from 2002 to 2025

About P/E Ratio at Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb P/E Ratio by Year

Bristol-Myers Squibb P/E Ratio 2025: 15.6×

Bristol-Myers Squibb P/E Ratio 2023: 13.0×

Bristol-Myers Squibb P/E Ratio 2022: 24.0×

Bristol-Myers Squibb P/E Ratio 2021: 19.2×

Bristol-Myers Squibb P/E Ratio 2019: 35.7×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Bristol-Myers Squibb (BMY) Key Financials